A new cancer vaccine has failed its primary-stage development trials. A story by MedPage Today reports that GlaxoSmithKline PLC (“GSK”) has announced its experimental cancer vaccine MAGE-A3 has failed to meet requirements to slow progressions to advanced stages of Melanoma.
This is a huge setback for the pharmaceutical giant. GSK claims the drug did not meet a primary goal in a late-stage trial in patients with melanoma, which was hoped to significantly extend the disease-free life of ...
continue reading...